{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:09:43Z","timestamp":1787436583860,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T00:00:00Z","timestamp":1570492800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T00:00:00Z","timestamp":1570492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81760539"],"award-info":[{"award-number":["81760539"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81560036, 81560034"],"award-info":[{"award-number":["81560036, 81560034"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Cooperation Program of Jiangxi Province","award":["20151BDH80043"],"award-info":[{"award-number":["20151BDH80043"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Although extensive use of tyrosine kinase inhibitors has resulted in high and durable response rate and prolonged survival time in patients with BCR-ABL1 positive chronic myeloid leukemia (CML) and acute leukemia, relapse and drug resistance still remain big challenges for clinicians. Monitoring the expression of BCR-ABL1 fusion gene and identifying ABL kinase mutations are effective means to predict disease relapse and resistance. However, the prognostic impact of BCR-ABL1 signal patterns detected by fluorescence in situ hybridization (FISH) remains largely unaddressed.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>BCR-ABL1 signal patterns were analyzed using FISH in 243 CML-chronic phase (CML-CP), 17 CML-blast phase (CML-BP) and 52 BCR-ABL1 positive acute lymphoblastic leukemia (ALL) patients.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The patterns of BCR-ABL1 signals presented complexity and diversity. A total of 12 BCR-ABL1 signals were observed in this cohort, including 1R1G2F, 1R1G1F, 2R1G1F, 1R2G1F, 2R2G1F, 1R2G2F, 1R1G3F, 1G3F, 2G3F, 1G4F, 1R1G4F and 1R4F. Complex BCR-ABL1 signal patterns (\u2265 two types of signal patterns) were observed in 52.9% (<jats:italic>n<\/jats:italic>\u2009=\u20099) of the CML-BP patients, followed by 30.8% (<jats:italic>n<\/jats:italic>\u2009=\u200916) of the ALL patients and only 2.1% (<jats:italic>n<\/jats:italic>\u2009=\u20095) of the CML-CP patients. More importantly, five clonal evolution patterns related to disease progression and relapse were observed, and patients with complex BCR-ABL1 signal patterns had a poorer overall survival (OS) time compared with those with single patterns (5.0 vs.15.0\u2009months, <jats:italic>p<\/jats:italic>\u2009=\u20090.006).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our data showed that complex BCR-ABL1 signal patterns were associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia. Monitoring BCR-ABL1 signal patterns might be an effective means to provide prognostic guidance and treatment choices for these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-019-6137-8","type":"journal-article","created":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T08:03:12Z","timestamp":1570521792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia"],"prefix":"10.1186","volume":"19","author":[{"given":"Zhanglin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lagen","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7765-5975","authenticated-orcid":false,"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,8]]},"reference":[{"key":"6137_CR1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ajh.24774","volume":"92","author":"F Castagnetti","year":"2017","unstructured":"Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, et al. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. Am J Hematol. 2017;92:797\u2013805.","journal-title":"Am J Hematol"},{"key":"6137_CR2","first-page":"1688","volume":"8","author":"JP Radich","year":"1994","unstructured":"Radich JP, Kopecky KJ, Boldt DH, Head D, Slovak ML, Babu R. Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction. Leukemia. 1994;8:1688\u201395.","journal-title":"Leukemia."},{"key":"6137_CR3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3109\/10428194.2012.701739","volume":"54","author":"S Konoplev","year":"2013","unstructured":"Konoplev S, Yin CC, Kornblau SM, Kantarjian HM, Konopleva M, Andreeff M, et al. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma. 2013;54:138\u201344. 2.","journal-title":"Leuk Lymphoma"},{"key":"6137_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.leu.2403241","volume":"18","author":"LS Steelman","year":"2004","unstructured":"Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE. McCubreyJA.JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 2004;18:189\u2013218.","journal-title":"Leukemia."},{"key":"6137_CR5","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.1038\/sj.onc.1205942","volume":"21","author":"S Xie","year":"2002","unstructured":"Xie S, Lin H, Sun T, Arlinghaus RB. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene. 2002;21:7137\u201346.","journal-title":"Oncogene."},{"key":"6137_CR6","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","volume":"114","author":"S Soverini","year":"2009","unstructured":"Soverini S, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S, et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood. 2009;114:2168\u201371.","journal-title":"Blood."},{"key":"6137_CR7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","volume":"102","author":"S Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276\u201383.","journal-title":"Blood."},{"key":"6137_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319\u201325.","journal-title":"Blood."},{"key":"6137_CR9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ajh.24625","volume":"92","author":"NJ Short","year":"2017","unstructured":"Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, et al. Poor outcomes associated with +der(22)t(9;22) and \u22129\/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017;92:238\u201343.","journal-title":"Am J Hematol"},{"key":"6137_CR10","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1309\/AJCPJCW6BY0CNIHD","volume":"135","author":"RL King","year":"2011","unstructured":"King RL, Naghashpour M, Watt CD, Morrissette JJ, Bagg A. A comparative analysis of molecular genetic and conventional cytogenetic detection of diagnostically important translocations in more than 400 cases of acute leukemia, highlighting the frequency of false-negative conventional cytogenetics. Am J Clin Pathol. 2011;135:921\u20138.","journal-title":"Am J Clin Pathol"},{"key":"6137_CR11","doi-asserted-by":"publisher","first-page":"582","DOI":"10.3324\/haematol.2009.014712","volume":"95","author":"TD Kim","year":"2010","unstructured":"Kim TD, Turkmen S, Schwarz M, Koca G, Nogai H, Bommer C, et al. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia. Haematologica. 2010;95:582\u20138.","journal-title":"Haematologica."},{"key":"6137_CR12","first-page":"164","volume":"32","author":"SR Bakshi","year":"2006","unstructured":"Bakshi SR, Brahmbhatt MM, Trivedi PJ, Shukla SN, Shah PM. Atypical D-FISH patterns of BCR\/ABL gene rearrangements in 169 chronic myeloid leukemia patients. J Assoc Genet Technol. 2006;32:164\u20137.","journal-title":"J Assoc Genet Technol"},{"key":"6137_CR13","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/sj.leu.2402963","volume":"17","author":"D Primo","year":"2003","unstructured":"Primo D, Tabernero MD, Rasillo A, Sayagues JM, Espinosa AB, Chillon MC, et al. Patterns of BCR\/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR\/ABL+ leukemias: incidence and underlying genetic abnormalities. Leukemia. 2003;17:1124\u20139.","journal-title":"Leukemia."},{"key":"6137_CR14","first-page":"991","volume":"86","author":"DS Lee","year":"2001","unstructured":"Lee DS, Kim EC, Yoon BH, Kim WH, Yoon JH, Cho HI. Can minor bcr\/abl translocation in acute leukemia be discriminated from major bcr\/abl by extra-signal FISH analysis? Haematologica. 2001;86:991\u20132.","journal-title":"Haematologica."},{"issue":"26","key":"6137_CR15","doi-asserted-by":"publisher","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","volume":"118","author":"A. Fabarius","year":"2011","unstructured":"Fabarius A, Leitner A, Hochhaus A, Muller MC, Hanfstein B, Haferlach C, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML study IV. Blood . 2011; 118:6760\u20136768.","journal-title":"Blood"},{"key":"6137_CR16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3109\/10428190009059278","volume":"38","author":"Z Beck","year":"2000","unstructured":"Beck Z, Kiss A, Toth FD, Szabo J, Bacsi A, Balogh E, et al. Alterations of P53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia. Leuk Lymphoma. 2000;38:587\u201397.","journal-title":"Leuk Lymphoma"},{"key":"6137_CR17","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1073\/pnas.0711824105","volume":"105","author":"SJ Zhang","year":"2008","unstructured":"Zhang SJ, Ma LY, Huang QH, Li G, Gu BW, Gao XD, et al. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2008;105:2076\u201381.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6137_CR18","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1002\/j.1460-2075.1994.tb06288.x","volume":"13","author":"K Mitani","year":"1994","unstructured":"Mitani K, Ogawa S, Tanaka T, Miyoshi H, Kurokawa M, Mano H, et al. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J. 1994;13:504\u201310.","journal-title":"EMBO J"},{"key":"6137_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/ajh.24943","volume":"93","author":"A Alhuraiji","year":"2018","unstructured":"Alhuraiji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, et al. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol. 2018;93:84\u201390.","journal-title":"Am J Hematol"},{"key":"6137_CR20","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","volume":"120","author":"S Luatti","year":"2012","unstructured":"Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I, et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA working party on CML analysis. Blood. 2012;120:761\u20137.","journal-title":"Blood."},{"key":"6137_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.4103\/0377-4929.101742","volume":"55","author":"PP Jain","year":"2012","unstructured":"Jain PP, Parihar M, Ahmed R, Abraham A, Vishwabandya A, George B, et al. Fluorescence in situ hybridization patterns of BCR\/ABL1 fusion in chronic myelogenous leukemia at diagnosis. Indian J Pathol Microbiol. 2012;55:347\u201351.","journal-title":"Indian J Pathol Microbiol"},{"issue":"5","key":"6137_CR22","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1182\/blood-2002-03-0777","volume":"100","author":"M. E. O'Dwyer","year":"2002","unstructured":"O'Dwyer ME, Mauro MJ, Kurilik G, Mori M, Balleisen S, Olson S, et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood . 2002; 100:1628\u20131633.","journal-title":"Blood"},{"key":"6137_CR23","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1038\/leu.2014.272","volume":"28","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Rinke J, Schafer V, Schnittger S, Kohlmann A, Obstfelder E, et al. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia. 2014;28:2292\u20139.","journal-title":"Leukemia."},{"key":"6137_CR24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","volume":"121","author":"JS Khorashad","year":"2013","unstructured":"Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 2013;121:489\u201398.","journal-title":"Blood."},{"key":"6137_CR25","doi-asserted-by":"publisher","first-page":"11306","DOI":"10.1073\/pnas.1608420113","volume":"113","author":"K Oshima","year":"2016","unstructured":"Oshima K, Khiabanian H, da Silva-Almeida AC, Tzoneva G, Abate F, Ambesi-Impiombato A, et al. Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2016;113:11306\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6137_CR26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-017-0434-y","volume":"10","author":"LW Ding","year":"2017","unstructured":"Ding LW, Sun QY, Mayakonda A, Tan KT, Chien W, Lin DC, et al. Mutational profiling of acute lymphoblastic leukemia with testicular relapse. J Hematol Oncol. 2017;10:65.","journal-title":"J Hematol Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6137-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6137-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6137-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T23:04:13Z","timestamp":1602025453000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6137-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,8]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6137"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6137-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,8]]},"assertion":[{"value":"15 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by Institutional Review Board from the first affiliated hospital of nanchang university and conducted in accordance with provision of the Declaration of Helsinki. Informed consent to participate in the study had been obtained from participants or their parents if the children were under 16.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"935"}}